Novo Nordisk, the Danish pharmaceutical giant known for its billions in obesity drug sales, has agreed to acquire German biotech firm Cardior Pharmaceuticals for €1.025 billion. This acquisition marks Novo Nordisk's strategic entry into the burgeoning field of therapeutic research using genetic information and RNA, specifically targeting cardiac diseases.

The company is leveraging its massive profits from the sales of Ozempic and Wegovy, medications for diabetes and obesity, to branch into other sectors, such as developing treatments for cardiac issues.

Cardior Pharmaceuticals was in an advanced stage of clinical trials for a new significant heart treatment. The deal is expected to be finalized in the second quarter.